Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Absci Corporation

Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to learn, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Our vision is to deliver breakthrough therapeutics at the click of a button, for everyone. 

Merck Global Health Innovation Fund

Casdin Capital

D1 Capital Partners

Fidelity

aMoon Fund

ArrowMark Partners

Fidelity Management and Research Company

Perceptive Advisors

Redmile Group

Helicase Venture

Irving Investors

Absci

We’re excited to announce our new strategic partnership with PrecisionLife. Under the partnership, we’ll be working together to discover and develop a shared pipeline of biotherapeutics for up to five mutually agreed-upon targets and indications. By combining our unique strengths, our goal is to create better therapies for patients with diseases that have long been challenging to treat.

Read more here: https://lnkd.in/gr3Qsp8b

#AI #Biologics #DrugDiscovery #PrecisionMedicine

For our annual Unlimiter Day this past Friday, employees from around the world gathered at our HQ in Vancouver, WA to celebrate our achievements in 2023 and plan for continued success in 2024 as we work with our new collaborators like AstraZeneca, Almirall, and PrecisionLife and continue developing our pipeline of new programs like our TL1A antibody ABS-101.

Then on Saturday, we put one of our core values, “We embrace our differences”, into action as Unlimiters volunteered with STEM Like a Girl to help build STEM kits that will be used in local schools to inspire participation in the sciences.

#AI #DrugDiscovery

Please enjoy my interview with Absci CEO Sean McClain

“We're on track to put the first de novo designed antibody with generative AI in the clinic in early 2025.”

Absci, a biotech startup using “generative AI” to create novel therapeutics, is hopefully just one year away from going into the clinic with its first design. That has already pushed Big Pharma to strike larger and larger deals with the company, says founder and CEO Sean McClain.

https://lnkd.in/eG6_MP6d

Absci
Sean McClain
#Investing #biotech #drugdevelopment #AI 

We are delighted to welcome Prof Sir Mene Pangalos to our Board of Directors and as Co-Chair of our Scientific Advisory Board. Mene brings a wealth of experience from his distinguished career, most recently as EVP of BioPharmaceuticals R&D at AstraZeneca. https://lnkd.in/grVddSSN

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover	0.11 -	0.05 48.99%	0.01 79.21%	0.02 59.56%	0.03 46.98%
cash per share	0.14 -	0.77 433.91%	5.08 557.55%	1.81 64.39%	1.06 41.37%
company equity multiplier	-0.47 -	-0.99 109.36%	1.16 217.54%	1.17 0.49%	1.23 5.44%
days of inventory outstanding
days of payables outstanding
days of sales outstanding	39.33 -	121.72 209.44%	108.77 10.64%	98.44 9.49%	139.73 41.94%
dividend yield
ebit per revenue	-3.04 -	-2.78 8.50%	-15.73 465.42%	-18.57 18.06%	-19.53 5.15%
ebt per ebit	1.05 -	1.08 2.68%	1.46 35.31%	0.99 32.40%	0.99 0.22%
effective tax rate	-0.03 -	-0.02 54.34%	0.08 638.26%	0.00 94.60%	0.00 79.31%
enterprise value multiple	-333.76 -	-150.61 54.88%	-1.75 98.84%	-1.68 3.94%	-3.33 97.91%
fixed asset turnover	0.41 -	0.36 13.15%	0.08 77.17%	0.10 21.44%	0.12 26.04%
free cash flow per share	-0.08 -	-0.15 84.45%	-1.99 1,264.39%	-1.07 45.94%	-0.71 33.70%
gross profit margin	1 -	1 0%	1 0%	1 0%	1 0%
interest coverage	-23.38 -	-20.98 10.26%	-21.92 4.49%	-109.83 400.97%	110.57 200.68%
inventory turnover
long term debt to capitalization	-0.11 -	-0.14 22.11%	0.04 125.78%	0.06 57.36%	0.05 12.26%
net income per ebt	1.03 -	1.02 1.73%	0.92 9.46%	1.00 8.34%	1.00 0.53%
net profit margin	-3.30 -	-3.05 7.68%	-21.11 592.69%	-18.25 13.54%	-19.34 5.93%
operating cash flow per share	-0.07 -	-0.12 81.86%	-1.22 904.78%	-0.90 26.59%	-0.70 21.56%
operating profit margin	-3.04 -	-2.78 8.50%	-15.73 465.42%	-18.57 18.06%	-19.53 5.15%
payables turnover
pretax profit margin	-3.20 -	-3.00 6.05%	-22.97 665.09%	-18.33 20.20%	-19.32 5.37%
price fair value	-47.41 -	-21.82 53.98%	1.11 105.10%	0.70 37.53%	2.19 215.58%
receivables turnover	9.28 -	3.00 67.68%	3.36 11.91%	3.71 10.49%	2.61 29.55%
return on assets	-0.35 -	-0.16 52.91%	-0.24 44.01%	-0.33 37.95%	-0.51 55.70%
return on capital employed	-0.39 -	-0.17 56.70%	-0.19 13.14%	-0.37 91.46%	-0.59 62.01%
return on equity	0.17 -	0.16 1.41%	-0.28 269.27%	-0.38 38.63%	-0.63 64.17%
total debt to capitalization	-0.17 -	-0.19 13.05%	0.05 126.78%	0.08 49.12%	0.06 22.03%

COM:ABSCI

Absci Corporation

Last Close

2.55

22/11 21:00

Market Cap

408.23M

Beta: -

Volume Today

1.09M

Avg: -

Preview